France
A new survey of French healthcare professionals reveals concerns that France is increasingly being excluded from major international clinical studies.
Leem, the French industry association, is reaching out to patients, carers and the general public with the aim of building better policies to improve access to medicines and ensure the pharmaceutical industry is competitive.
France is preparing to roll out a fast‑track pathway that offers the possibility of 14-day approvals for applications of certain early‑phase national trials, adding fresh momentum to the race for clinical research leadership among countries in the EU.
Aqemia uses proprietary physics-based solvers paired with generative AI to discover genuinely novel drug candidates, bypassing historical training data to crack targets others cannot.
Sanofi’s EVP Madeleine Roach details ways in which snackable, generative and expert AI are transforming innovation, helping halve the time for a drug to move from discovery to market. AI has aided a cut in mRNA design time by 50% at the "first AI-powered biopharma at scale."
BC Partners has completed its acquisition from Servier of French generics giant Biogaran after the French government allowed the private-equity takeover on condition that BPI France take a minority stake. Meanwhile, former Biogaran CEO Erick Roche has returned to the role after a long stint at Teva.
While the regulatory environment for vaccines sours in the US, Valneva tells Scrip it is mulling an Asia hub and finalizing a strategy - that includes partnerships - for its marketed and pipeline products. Could it consider India or China as a new regional center?
A year after Valneva entered a tech transfer agreement for its chikungunya vaccine with Serum Institute, the deal has been called off. Regulatory approvals for the vaccine in Asia are yet to be obtained and the biologics license for Ixchiq remains suspended in the US. What happens hereon?
The French national assembly has adopted a version of the 2026 social security finance bill that includes price cuts and penalties for companies that adopt tactics to delay generic entry.
Deal Snapshot: Days after the disappointment of a mid-stage fail for its rare disease fidrisertib, Ipsen has hit the M&A trail to boost its oncology efforts and license an antibody-drug conjugate (ADC) from Simcere Zaiming.
The Paris-headquartered giant has put the spotlight on its extensive investments at home.
France is set to pilot a new fast-track process that could more than halve the timeline for authorizing certain clinical trial applications.